| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C35H38N4O6 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Manidipine is an orally active calcium channel antagonist that modulates the expression of the cytokines IL-1β and IL-6. It produces a hypotensive effect and can be used in the study of cardiovascular conditions such as hypertension, myocardial ischemia-reperfusion injury and ventricular hypertrophy, kidney conditions such as glomerular diseases, and epilepsy[1][2][3][4][5][6][7][8]. It is supplied as a light yellow to yellow solid (C35H38N4O6, MW 610.70) at 99.92% purity.
Physical & Chemical Properties
| CAS Number | 89226-50-6 |
|---|---|
| Molecular Formula | C35H38N4O6 |
| Molecular Weight | 610.70 g/mol |
| Purity | 99.92% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3 |
| Signaling Pathway | Membrane Transporter/Ion Channel; Neuronal Signaling; Immunology/Inflammation |
| Solubility | In Vitro: DMSO: 100 mg/mL (163.75 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[8]. Souza C N S, et al. 074—(SOA0068) Anticonvulsant activity of acute treatment with manidipine in pentylenetetrazole-and pilocarpine-induced seizure models in mice. Epilepsy & Behavior, 2014, 38: 214.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (163.75 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
In human mesangial cells stimulated by PDGF-BB, Manidipine (1 nM-1 μM; 1-4 h) suppresses mRNA transcription of IL-1β and GM-CSF while enhancing IL-6 gene transcription[1]. In A7r5 cells and glomerular mesangial cells, Manidipine (0.1 nM-1 μM; 20-60 min) blocks the ET-1-induced [Ca2+]i increase[2]. Manidipine (1-5 μM; 18 h) completely suppresses IL-6 production triggered by acLDL, oxLDL or TNF-α in human endothelial cells[3].
In Vivo
In normocholesterolemic rats, Manidipine (1-10 mg/kg; p.o.; once a day; 7 days) lowers systolic blood pressure, raises plasma nitrite/nitrates, and exerts a cardioprotective effect against ischemia-reperfusion injury that is dose-dependent[6]. In rats, Manidipine hydrochloride (3 mg/kg; i.g.; once a day; 7 days) prevents left ventricular hypertrophy induced by Isoproterenol, along with the rise in ANP, collagen types I and III, and fibronectin mRNAs[4]. In spontaneously hypertensive rats, Manidipine hydrochloride (0.05% in rat chow; p.o.; 2 months or 20 μg/kg; i.v.) has an antihypertensive effect[5]. In PTZ-induced seizure mice, Manidipine (10-30 mg/kg; i.p.; given before the agents that induced seizures) lengthens the latency to convulsions and the time of death[8].
| Animal Model | Male Spontaneously Hypertensive Rats (SHR) (age 8 weeks); Chronic hypertension renal microcirculation model and acute hypertension renal microcirculation model[5] |
|---|---|
| Dosage | 0.05% in rat chow (chronic), 20 μg/kg (acute) |
| Administration | Oral administration (chronic, 2 months); Intravenous injection (acute, once) |
| Result | Reduced systemic blood pressure, increased renal blood flow by dilating the afferent arterioles, and improved glomerular hypertension by dilating the efferent arterioles in the chronic model. Decreased systemic blood pressure in the acute model. Had different effects on renal microcirculation parameters, such as no significant change in SNGFR, SNGPF, or ΔP in some cases. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Regulation of P-glycoprotein through CaMKII/cPLA2 pathway in lymphocytes for treating refractory rheumatoid arthritis by manidipine. Int Immunopharmacol 2025 May 27:156:114735. PMID: 40294472
Docking and database screening identify manidipine as a potential modulator of matrix metalloproteinase-7 in chronic kidney disease. Biomed Pharmacother 2025 Dec:193:118748. PMID: 41232355
Drug-induced phospholipidosis as an artifact in antiviral drug repurposing. bioRxiv 2025 Nov 21:2025.11.20.689520. PMID: 41332603
